Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04468204 · ClinicalTrials.gov registry record · NA

Use of Novel Sinusonic Device for Prevention of Community Acquired Upper Respiratory Infection (URI)

A NA study, sponsored by Medical University of South Carolina.

Completed
Registry status
NA
Development phase
95
Enrollment target

NCT04468204: Completed NA study, sponsored by Medical University of South Carolina.

NCT04468204 is a NA study that has completed, run by Medical University of South Carolina. The registered enrollment target is 95 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04468204, a NA study, has completed, sponsored by Medical University of South Carolina.

COMPLETED
Registry status
NA
Development phase
95 participants
Enrollment target

Study Summary

This study aims to test the safety, efficacy and potential mechanism of action of the SinuSonic device on adults with upper respiratory infection (URI). SinuSonic is a medical device that utilizes sound and pressure combined with normal breathing. The study will have 2 aims. Aim 1 willdetermine if Sinusonic decreases the number of URIs experienced during an 8 week fall URI season. Subjects will use an active device (positive expiratory pressure and 128 Hz) or a sham device (no positive expiratory pressure and 1,000 Hz) for 1 min tid for 8 weeks. Aim 2 will determine if Sinusonic decreases the severity and duration of community acquired viral URIs. Subjects will use active or sham device as above.

Primary Outcome

The Total Symptom Score (TSS) was based on the severity of each of upper respiratory infection (URI) symptom. The TSS includes 9 symptoms: Lost sense of smell/taste, sneezing, runny nose or thick nasal discharge, nasal obstruction or congestion, sore throat, cough headache, maliase, and chilliness. The severity of URI symptoms was scored on a symptom severity scale (0 = not at all; 1 = mild symptoms; 2 = moderate symptoms; 3 = severe symptoms) Minimum score=0; maximum score=27.

Interventions

  • DEVICE SinuSonic Device
  • DEVICE Sham SinuSonic Device

Trial Details

FieldValue
Enrollment Target 95 participants
Start Date 2020-10-01
Est. Completion 2021-07-01
Phase NA

What the finished NCT04468204 record still lists

NCT04468204 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 95 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower).

The record links to 0 conditions, and to 2 interventions - of which SinuSonic Device is the first listed.

NCT04468204 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT04468204 about?

NCT04468204 is a clinical study titled "Use of Novel Sinusonic Device for Prevention of Community Acquired Upper Respiratory Infection (URI)". This study aims to test the safety, efficacy and potential mechanism of action of the SinuSonic device on adults with upper respiratory infection (URI). SinuSonic is a medical device that utilizes sound and pressure combined with normal breathing. The study will have 2 aims. Aim 1 willdetermine if S...

What is the current status of trial NCT04468204?

This trial is currently completed. It is a NA study. The enrollment target is 95 participants. The study started on 2020-10-01. Estimated completion is 2021-07-01.

What interventions are being tested in trial NCT04468204?

The interventions under investigation include: SinuSonic Device (DEVICE), Sham SinuSonic Device (DEVICE).

Who is sponsoring clinical trial NCT04468204?

This trial is sponsored by Medical University of South Carolina, which has 755 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT04468204's enrollment target sits among peer trials

95 931st of 2000 higher than 1,066 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03339128 · 95 participants · Phase 2

    Study to Explore the Therapeutic Effect of Eluxadoline in Treating Irritable Bowel Syndrome With Diarrhea in Children

  • NCT03509961 · 95 participants · Phase 2

    The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL

  • NCT03694756 · 95 participants · NA

    TMEM-MRI: A Pilot Feasibility Study of MRI for Imaging of TMEM in Patients With Operable Breast Cancer

  • NCT04206215 · 95 participants · NA

    Noninvasive Brain Stimulation for Treating Carpal Tunnel Syndrome

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04468204, the US trial registry maintained by the National Library of Medicine. NCT04468204 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.